Design: A double blind, randomised controlled trial using 40 hospital referred patients with CMCJ osteoarthritis who received intra-articular injections of 5 mg triamcinolone hexacetonide (0.25 ml) or ...

Exclusion criteria included: An intra-articular injection of any substance administered within the last 3 months, joint inflammatory diseases, microcrystalline arthropathies, current pregnancy ...

that reported on the occurrence of adverse events after intervention with local non-intra-articular corticosteroid injections were included. Studies concerning epidural injection and ...

Mario Tama / Getty Images Shares of Intra-Cellular Therapies jumped Monday morning after Johnson & Johnson announced plans to buy the biopharmaceutical company. Intra-Cellular shareholders will ...

Johnson & Johnson will acquire Intra-Cellular Therapies for $132 per share in a deal that values the company at $14.6 billion. The acquisition includes FDA-approved CAPLYTA for schizophrenia and ...

Jan 12 (Reuters) - Drug maker Johnson & Johnson (JNJ.N), opens new tab is exploring a bid to acquire Intra-Cellular Therapies (ITCI.O), opens new tab, a biopharmaceutical company, Bloomberg News ...

Johnson & Johnson will acquire Intra-Cellular for $132 per share in cash, a 39 percent premium over Intra-Cellular's Friday closing price of $94.87. Following the announcement, shares of both ...

Johnson & Johnson has opened the J.P. Morgan Healthcare Conference with a bang, buying out Intra-Cellular Therapies for $14.6 billion. At $132 per share, J&J paid a 39% premium on Friday’s ...

Johnson & Johnson JNJ4.13%increase; green up pointing triangle agreed to acquire mental-illness drug developer Intra-Cellular Therapies ITCI-0.11%decrease; red down pointing triangle for about $15 ...

Intra-Cellular Therapies ITCI signed a definitive agreement with pharma bigwig Johnson & Johnson JNJ. Per the terms, the pharma giant will acquire all outstanding shares of ITCI for $132 per share ...

Intra-Cellular Therapies (ITCI) shares soared 14.9% in the last trading session to close at $94.87. The move was backed by solid volume with far more shares changing hands than in a normal session.

Johnson & Johnson said Monday it would buy Intra-Cellular Therapies in a deal worth $14.6 billion, another sign of large drugmakers’ reentry into neuroscience and a sizable purchase that will ...